What Darzalex Treats: Main Uses and Benefits

Darzalex (daratumumab) is commonly used to help manage Multiple Myeloma (MM), a serious condition. Its therapeutic role is relevant across the full course of the disease.

The medication is commonly used across conditions characterized by periods of heightened symptoms and where symptoms create noticeable physiological strain. It is applied for patients who are newly diagnosed and those managing relapsed or refractory manifestations—situations where the condition has returned or previously failed to respond to other treatments.

---

Supporting Disease Stability and Comfort

The treatment may assist with achieving a strong level of disease suppression, which is considered relevant for patient care. This supports the patient in maintaining a period of disease stability and assists with maintaining functional stability during the course of the condition. By addressing the disease activity, the treatment is commonly used to help with managing symptoms related to systemic imbalance that may be associated with the active condition.

This supports the patient during difficult episodes by easing distress from symptoms that interfere with daily functioning, such as pronounced fatigue and physical discomfort.

---

Quick Fact: Support for Symptom Management	Details
Primary Indication	Multiple Myeloma (MM)
Clinical Situations	Newly diagnosed, relapsed, and refractory disease
Symptoms Addressed	Systemic imbalance, pronounced fatigue, physical discomfort

Regulatory References

1. European Medicines Agency (EMA) Darzalex Overview

Darzalex is approved exclusively for use in adult patients with certain conditions, including multiple myeloma, high-risk smoldering multiple myeloma, and newly diagnosed AL Amyloidosis. Eligibility is strictly defined by regulatory documents, which establish specific exclusions and conditional requirements.

Who Cannot Use Darzalex

Classification	Eligibility Rule (Official Restriction)
Contraindicated	Patients with a history of severe hypersensitivity (e.g., anaphylaxis) to daratumumab or any component of the formulation are absolutely prohibited from use.
Not Recommended	Use is not recommended for pregnant women due to the potential for fetal harm (Embryo-Fetal Toxicity) or for breastfeeding patients.
Not Recommended	Patients with the AL Amyloidosis indication who also have severe cardiac disease (NYHA Class IIIB or IV or Mayo Stage IIIB) are not recommended for treatment outside of controlled clinical trials.

Population-Specific Restrictions

• Pediatric Patients: Safety and effectiveness have not been established in the pediatric population (patients under 18 years).
• Reproductive Potential: Females who are able to become pregnant must use effective contraception during therapy and for at least 3 months after the final dose.
• Organ Function: No dose adjustments are necessary for patients with renal impairment or mild hepatic impairment; however, the drug has not been studied in moderate or severe hepatic impairment.

Interactions with other medicines and products

Regulatory documentation defines the interaction profile for Darzalex (daratumumab) based on constraints related to concomitant medications and diagnostic testing interference.

Documented Interaction Constraints

The most significant interaction is the pharmacodynamic interference with certain diagnostic laboratory procedures. Darzalex binds to the CD38 protein found on red blood cells (RBCs), which can lead to false positive results when performing serologic testing, specifically cross-matching and red blood cell antibody screening (Indirect Antiglobulin Test or IAT). This procedural interaction is a mandatory regulatory caution that may persist for up to six months following the final infusion.

Mandatory sequencing rules apply to several concomitant medicines:

• Pre-infusion Medications: Corticosteroids (e.g., dexamethasone), antipyretics, and antihistamines must be administered 1 to 3 hours prior to every Darzalex infusion.
• Timing Restriction: Corticosteroids used as part of the background multiple myeloma regimen (e.g., prednisone) are prohibited on Darzalex infusion days if a different corticosteroid is used for pre-medication.
• Antiviral Prophylaxis: Initiation of antiviral prophylaxis is required within one week of starting treatment and must continue for three months following treatment completion.

No pharmacokinetic interactions related to CYP enzymes, drug transporters, food, alcohol, or herbal products are documented in regulatory labeling.

How Darzalex Works

Targeting and Elimination of CD38-Expressing Cells

The drug's activity is focused on the CD38 protein, a transmembrane glycoprotein found on the surface of specific cell types. The drug, an antibody, binds to CD38 with high affinity, initiating a molecular tagging process. This binding activates multiple simultaneous cell-destruction pathways: Complement-Dependent Cytotoxicity (CDC), which uses plasma proteins to lyse the cell; Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), which recruits immune effector cells; and direct apoptosis, causing the cell to self-destruct. This multi-pronged attack results in the systemic reduction of the targeted cell population.

Modulating the Body's Immune Response

Beyond direct elimination, the mechanism also influences the peripheral immune environment. The drug targets and clears specific CD38-expressing immune cells that normally function to suppress immune activity, such as T-regulatory cells. By clearing these regulatory components, the drug indirectly alters the activity of other immune cells. This action results in a modulation of the immune environment related to the targeted cell population.

Darzalex (daratumumab) is administered in a highly structured, long-term protocol that proceeds through distinct phases, with the frequency of use decreasing over time. The medicine is provided through two distinct routes: as an Intravenous (IV) infusion of Darzalex concentrate, or as a Subcutaneous (SC) injection of Darzalex Faspro, which contains daratumumab co-formulated with hyaluronidase.

The dosing regimen is based on the specific formulation. The standard IV infusion dose is calculated as 16 mg/kg of the patient's actual body weight. In contrast, the SC route uses a fixed dose of 1,800 mg, which remains constant regardless of the patient's weight. No dose reductions are generally recommended; only dose delays may be used to manage certain reactions.

Administration follows a cyclic and phased schedule: an initial period of weekly dosing (Induction Phase) is followed by less frequent administration (Consolidation Phase), ultimately transitioning to a monthly schedule (Maintenance Phase). All administration, regardless of the route, must take place in a supervised medical setting. Specific pre- and post-administration medications (such as corticosteroids and antihistamines) are required to be given to the patient. No specific dose adjustment is needed for patients with mild hepatic impairment. If a dose is missed, the procedure is to administer it as soon as possible and adjust the schedule to maintain the proper interval.

Research evidence / Overview of studies for Darzalex

Evidence for Newly Diagnosed Multiple Myeloma in Transplant-Ineligible Patients

This section will summarize the research structure, including the large Phase 3 randomized trials that studied daratumumab combinations as a first-line therapy for patients who are not candidates for a transplant, and what key survival and response outcomes were measured.

Research for daratumumab in newly diagnosed patients who are not eligible for an autologous stem cell transplant (ASCT) has centered on large, international Phase 3 Randomized Controlled Trials (RCTs). These studies were designed to compare treatment regimens containing daratumumab plus standard therapy against the standard therapy alone. Researchers examined important long-term outcomes, including Overall Survival (OS) and Progression-Free Survival (PFS), and monitored the depth of response, including Minimal Residual Disease (MRD) negativity. Final trial analyses reported measurements of Overall Survival, with follow-up periods extending up to seven years in some of the key RCTs. Data characterizing specific outcomes for highly frail subgroups may still be limited.

---

Studies for Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

This section will provide an overview of the key studies that examined daratumumab as part of the induction, consolidation, and maintenance regimen before and after autologous stem cell transplant, and the measurable disease control endpoints the researchers evaluated.

Research for patients who are eligible for a stem cell transplant was conducted using several key Phase 3 RCTs. The studies monitored the depth of response and the duration of response, including the percentage of patients achieving MRD negativity. The long-term outcomes for Overall Survival for all induction and maintenance regimens are still maturing in ongoing analyses. Additionally, the precise pattern observed during the immediate post-transplant maintenance phase is difficult to separate from the observations related to the preceding intensive therapy.

---

Research for Relapsed or Refractory Multiple Myeloma

This section will describe the randomized controlled trials and pooled analyses that evaluated daratumumab combinations and monotherapy for patients whose disease has returned or become resistant to prior treatments, and the specific endpoints examined in those studies.

The research base for Relapsed or Refractory Multiple Myeloma (RRMM) includes large Phase 3 RCTs that compared daratumumab combinations against standard combinations. Earlier Phase 2, single-arm studies also monitored the effect of daratumumab used alone (monotherapy). Studies primarily monitored Overall Survival (OS), Progression-Free Survival (PFS), and the Overall Response Rate (ORR). The studies reported measurements of both PFS and OS, with final analyses spanning up to seven years. Evidence remains heterogeneous across the many different types of previous therapies patients may have received.

---

Long-Term Outcomes and Durability of Research Data

This section will summarize the extent of the follow-up data available across all indications, including what is known about the maximum observed follow-up duration for deep responses and the long-term survival measurements reported in final trial analyses.

Research has explored the durability of responses across all major indications. The final analyses of key Phase 3 trials have described patterns in patient progression that have been monitored for periods of five to seven years. These long-term studies help show what has been observed so far regarding the continuity of responses in daratumumab-based regimens. There is limited information for outcomes that extend beyond the maximum follow-up duration of the research conducted to date.

---

Evidence in Specific Patient Populations and Subgroups

This section will outline the research conducted on particular groups, such as older adults, patients with high-risk genetic features, those who are heavily pre-treated, and patients with high-risk smoldering multiple myeloma.

Darzalex was evaluated in specific subgroups, including older adults in the transplant-ineligible setting and for patients presenting with high-risk genetic features. Research also describes findings related to heavily pre-treated patients. Additionally, daratumumab was studied for High-Risk Smoldering Multiple Myeloma (HR-SMM), a precursor condition. Findings describe patterns observed in the time elapsed until progression was recorded. Data for certain groups remain insufficient, and the evidence quality varies across studies when moving away from the main approved indications.

---

What is Still Uncertain About the Research

This section will clarify the main evidence gaps and areas where regulatory agencies or scientific literature have noted a lack of long-term data, inconsistency across specific comparative regimens, or where research is still developing.

Certainty remains low in certain areas. For example, while long-term data for Overall Survival is available for the main indications, long-term effects beyond seven years are not fully established. Similarly, study results apply only to the populations studied; limited data are available for highly specific, small subgroups. Research is ongoing to fully describe the long-term patterns for all possible combination regimens. For emerging indications, such as High-Risk Smoldering Multiple Myeloma, long-term outcomes are not fully established. Findings describe group patterns, and research provides context but not individual predictions.

Common questions about Darzalex (FAQ)

Q: What kind of side effects are common with Darzalex?

A: Official regulatory documentation describes certain side effects as very common, meaning they may affect more than 1 in 5 patients. These frequently reported events include infusion-related reactions (IRRs), upper respiratory tract infection, fatigue, and gastrointestinal issues like nausea and diarrhea. Changes in blood cell counts, such as low white blood cell counts (neutropenia), are also listed as very common.

Q: What is the total duration of Darzalex treatment typically?

A: The duration of treatment is structured with scheduled cycles that proceed through different phases, with the frequency of administration decreasing over time. In general, treatment often continues until the underlying disease progresses or if the medicine is no longer tolerated. For certain patients who receive a stem cell transplant, a fixed number of doses may be planned for the pre- and post-transplant regimens.

Q: Can Darzalex affect my immune system long-term?

A: The medicine is designed to affect specific immune cells that carry the CD38 protein. Due to this action, the drug is associated with certain effects on the immune system, including common side effects like low white blood cell counts and a serious risk of infections, which can persist during and after treatment. Official information emphasizes the importance of antiviral prophylaxis and monitoring for signs of infection.

Q: Are there any foods or supplements to avoid while on Darzalex?

A: Official regulatory documentation and product labeling do not identify any specific pharmacokinetic interactions between Darzalex and common items such as food, alcohol, or herbal products. Information regarding specific diet, supplement, or medication use should be discussed within a medical context.

Q: Is Darzalex used for any cancers besides multiple myeloma?

A: According to the official product information, Darzalex is indicated for the treatment of multiple myeloma and is also approved for the treatment of specific adult patients with light chain (AL) amyloidosis. AL amyloidosis is a disorder involving plasma cells that is related to multiple myeloma.

Q: What research has been done on Darzalex for older adults?

A: Clinical trials for patients who are not eligible for a stem cell transplant included groups of older adults. The research reviewed the safety profile and effectiveness in these subgroups and generally found the outcomes to be consistent with those seen in the overall study population.

Q: Can I take vaccines while I am receiving Darzalex?

A: Regulatory documents advise caution regarding certain immunizations. The safety of using live attenuated vaccines (which contain a weakened form of the live virus) has not been established. Live attenuated vaccines are generally noted to be avoided during and following the treatment period due to the drug’s effects on immune cells.

Q: What does the full treatment course with Darzalex involve?

A: The full treatment course is highly structured and involves receiving the medicine in a supervised medical setting according to a phased schedule (starting weekly and becoming less frequent). Additionally, specific pre- and post-administration medications (such as corticosteroids and antihistamines) are required for the treatment.

Q: Can Darzalex cause changes in blood sugar levels?

A: Clinical trial data lists hyperglycemia (high blood sugar) as a reported side effect. This is also relevant because corticosteroid medications are required as part of the treatment's pre-medications for the infusion, and corticosteroids are known to affect blood sugar regulation.

Q: Is the first Darzalex treatment longer than the others?

A: The official product information states that the first intravenous (IV) infusion of Darzalex typically requires a longer administration time compared to later infusions. There is an option to split the first dose over two consecutive days to help shorten the time needed for the infusion on each day.

Q: Do people feel sick immediately after getting Darzalex?

A: Infusion-related reactions (IRRs) are very common with the treatment. Official regulatory documentation states that nearly all of these reactions occurred during the infusion or within 4 hours of completing the infusion. These reactions can include symptoms such as chills, nausea, vomiting, or difficulty breathing, which is why the treatment is given in a supervised setting.

Q: Can Darzalex cause an allergic reaction?

A: Yes, Darzalex is known to cause administration-related reactions, which include the potential for serious allergic-type reactions, such as anaphylaxis. For this reason, the medicine is contraindicated (absolutely prohibited) for patients who have previously had a severe hypersensitivity reaction to Darzalex.

Q: What is the chance of having an infusion-related reaction?

A: Infusion-related reactions (IRRs) are very common, with the highest incidence occurring during the first administration. Clinical trial data indicates that the chance of having an IRR during the very first infusion was reported in a high percentage of patients (e.g., 37% to 42% depending on the regimen). The rate of these reactions is typically much lower with subsequent infusions.

Q: Are there specific side effects that men or women experience more often?

A: Official regulatory documents indicate that while minor differences in the amount of the drug in the body were noted between male and female patients, this difference is not considered clinically meaningful. Therefore, no individual dose adjustment is necessary based on the patient's sex.

Q: What is the mechanism of action of Darzalex?

A: The medicine is formally defined in regulatory documents as a CD38-directed cytolytic antibody. This means it is designed to target the CD38 protein found on cancer cells and destroy them through multiple pathways, including the activation of the body's immune defenses and direct cell death (apoptosis).

Q: Can Darzalex be used for AL amyloidosis?

A: The medicine is approved for the treatment of certain adult patients with light chain (AL) amyloidosis. However, official labeling notes that its use is not recommended for AL amyloidosis patients who also have severe cardiac disease (classified as NYHA Class IIIB or IV or Mayo Stage IIIB) outside of controlled clinical trials.

Q: Can Darzalex change a person's mood or cause anxiety?

A: Specific mood changes or anxiety are not consistently listed among the most frequently reported side effects in official documentation. However, the known side effect profile includes reports of insomnia (difficulty sleeping) and a general feeling of asthenia (physical weakness or lack of energy).

Q: Does Darzalex cause hair loss?

A: Based on official regulatory documentation from clinical trials, hair loss (alopecia) is not reported as one of the very common, common, or serious side effects associated with Darzalex.

Q: How does Darzalex affect the liver or heart?

A: The medicine has not been well studied in patients with moderate or severe liver (hepatic) impairment. For patients being treated for light chain (AL) amyloidosis, a warning exists regarding the potential for cardiac toxicity (heart damage), which requires careful monitoring for heart-related adverse reactions.

How to Store and Dispose of Darzalex (Daratumumab) and Darzalex Faspro

The storage and disposal of Darzalex products must strictly follow regulatory requirements to maintain product stability.

---

Storage Requirements

Condition	Requirement
Temperature	Unopened vials must be stored refrigerated between 2 C and 8 C (36 F to 46 F).
Protection	Store in the original carton to protect the contents from light.
Handling	Do not freeze the vials; the unopened vial must not be shaken.
Child Safety	Keep the product out of the sight and reach of children.

---

Stability and Disposal

The prepared or diluted solution for injection has a limited stability time (e.g., 15 to 24 hours) at room or refrigerated temperatures and must be discarded if this time limit is exceeded. Any unused product or waste material must be disposed of according to local requirements for pharmaceutical waste. The medicine must not be disposed of via wastewater or in household trash.